Extract Alpha from Financial Content

AI Infrastructure

AI demand remains substantial, but financing costs, rates, and execution are separating durable opportunities from speculative capacity build-outs. NVDA adds company-specific governance and export-control uncertainty, so confirmation matters more than dip-buying.

• Nebius (NBIS): Preferred neocloud relative to IREN in one discussion; verify financing, signed contracts, and deployment, with November 12 earnings carrying an options-implied move near 30%.
• CoreWeave (CRWV): Q3 revenue rose 168% to $3.7B and 2026 guidance is $13–$13.3B, but debt costs, backlog conversion, and delivery remain central risks.
• NVIDIA (NVDA): Monitor the independent investigation, China-related allegations, and export controls; unresolved claims and higher yields make volatility likely, not a clear dip-buy signal.
• AI power (VST, CEG): Data-center demand supports a diversified exposure; confirm contract resilience if projects slow, while Bloom Energy’s negative cash flow and valuation raise execution risk.

Chips And Connectivity

The semiconductor selloff may create openings, but rate pressure and possible capex growth peaking in 2027 argue against treating every decline as a bargain. Prefer evidence of earnings and customer demand over momentum.

• Onto Innovation (ONTO): Beat results and guidance, with management forecasting 45% growth in 2026; upcoming results can test whether demand sustains the outlook.
• Broadcom (AVGO) and AMD (AMD): Potential AI-chip alternatives amid investor rotation, but both remain exposed to semiconductor weakness and uncertain AI spending; avoid chasing sharp moves.
• Credo (CRDO): Highlighted as a lower-valuation AI-connectivity alternative to Marvell; smaller-cap volatility and the broader selloff remain significant risks.

Healthcare And Platforms

Longer-duration growth stories hinge on durable adoption and sound unit economics, while established platforms may benefit as investors broaden beyond semiconductor leaders. Execution and valuation remain key filters.

• Hims & Hers (HIMS): Growth, international expansion, and new GLP-1 offerings are potential drivers; track subscribers, revenue per user, margins, and marketing efficiency before treating them as proven.
• Eli Lilly (LLY) and Novo Nordisk (NVO): GLP-1 demand is a long-term theme; watch whether volume growth offsets price cuts and competition rather than assuming share gains.
• Uber (UBER): Q3 revenue rose 10% to $14.8B and adjusted EPS 35% to $0.88; Q4 EPS guidance of $0.95–$0.99 is balanced by investment and competition risks.